Emcure Pharmaceuticals Limited IPO (Emcure Pharma IPO) Detail

Emcure Bouncing back slowly.

Hold or sell ??

​@Admin @ Chittorgarh.com Under stock price info, 52W low price has not been updated. It has gone below Rs 1287 whereas CG's data shows Rs 1325.05
Kindly arrange make necessary correction.

​@Admin @ Chittorgarh.com @Prachi @ Team Chittorgarh.com Kindly correct the data, it is still showing old/wrong one and has not been updated

How to open axis joint a/c in which both a/c holders can apply IPO?

Check with the Bank, if they issue separate IDs for each of joint account holder linked to respective PAN - it is all good.

Should we hold or sell

Nice question 😊
One needs to find the answer all by oneself, though.

Today also falling like crazy. Budget me aisa kya ho sakta jo isko effect karegi? Abse first 2 days me hi bech dena hai, 1 month wait karke koi fayda nahi, most can't even beat listing price. Wait karna hai toh 2 months is minimum, uske pehele patience check hoti hai.

Irony is easemytrip is one of the topgainers today, so industry wise toh koi issue nahi dikh raha.

​@HumorHedge bhai i am stuck with this easemytrip share, waiting to reach atleast 50... did a wrong entry due to calls.

Emcure Pharmaceuticals LTD :
A Detailed Analysis✨

🟩Introduction🟩

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune, India. Founded in 1981

🟩Key Points 🟩

1️⃣Emcure Develops, Manufactures & Markets a wide range of

(1/17)
formulations and APIs, with a Diverse portfolio of orals, injectables, and biotherapeutics
pharmaceutical products across several major therapeutic areas as Below with detailed Revenue share :

Gynecology 24.09%
Cardiovascular 15.7%
Anti-infectives 10.97%

(2/17)
Vitamins & Nutri. 8.97%
HIV antivirals 6.85%
Respiratory 6.35%
Gastrointestinal 6.35%
Pain & analgesics 5.48%
Blood-related 3.84%
Oncology 4.46%
& Other

2️⃣ Worldwide/Global presence :
The company's products reach

(3/17)
over 70 countries worldwide including India

🟩Geographical Revenue Bifurcation :

India 48.28%,
Europe 21.38%
North America 13.94%
Others 16.4%

Thus 50% in India and 50% International Revenue which is Good Mix of geographical business

(4/17)
3️⃣Market Leadership :

Emcure is ranked 13th in domestic sales and 4️⃣th Largest in its covered Market for FY24.

It is the "Largest pharmaceutical" company in the
"Gynecology and HIV antivirals" therapeutic areas in terms of domestic sales for MAT FY2024

(5/17)
4️⃣ Strong R&D :

Emcure has 548 scientists and 5 R&D facilities in India,

with over 1,800 global dossiers filed including 209 in the EU and 142 in Canada &
"220 patents granted"

5️⃣ Extensive Distribution Network:

Emcure's distribution network is supported by over 5,000

(6/17)
Personnel regularly interacting with healthcare providers to promote its products.

6️⃣ Strategic Acquisitions:

Emcure has made Many Fruitful strategic acquisitions as Follows :

In 2023 Acquired
Mantra Pharma Inc to expand its global presence and product portfolio.

(7/17)
In 2016 Acquired
Bhardwaj Pharma GmbH (now known as Tillomed Pharma GmbH

In 2015 Acquired
Marcan Pharmaceuticals Inc. Canada

7️⃣ Financial Performance :

Emcure has shown consistent growth in its financial performance over the past few years.
In FY24 company reported

(8/17)
Revenue of ₹6,715 cr and PAT of ₹528 cr. The company's net profit margin was 8%.

8️⃣ IPO :
Fresh issue proceeds of 800 cr Will be used for :

📌 Debt repayment of 600 cr Which will Reduce D/E & Intrest cost

📌 Rest 200 cr will be used

(9/17)
for working capital to add 1000 new sales personnel for more Revenue growth and
Other operations of company

9️⃣
Capacity Addition :
Emcure have total 1️⃣3️⃣ Manufacturing facilities and

They added 4️⃣ new manufacturing facilities in past some years using debt

(10/17)
that's why Emcure having debt right now but it will eventually reduce

Company never delayed to repay debt on time that's why it has "high safety grade" ratings of AA Stable from rating agency

They have enough Capacity to Meet Growing demand and Generate more Revenue

(11/17)
1️⃣0️⃣
Emcure & Sanofi Partnership :

📌
High-Margin Products:
The deal involves collaboration on cardiology products, which typically have higher margins than Emcure's current product portfolio. This can boost Emcure's profitability.

📌
Market Access and Brand Boost :

(12/17)
Sanofi is a major pharmaceutical player globally. Partnering with them can give Emcure access to Sanofi's distribution network and brand reputation, potentially increasing Emcure's sales in India and abroad.

💠🔷Investment Highlights🔷💠

(13/17)
1️⃣ Experienced and Qualified Promoters :

Namita Thapar who is a visionary leader with a clear focus on growth & Innovations , handling the woman care department and she is focused to improvise the healthcare of women population of our country which has immense potential

(14/17)
To Grow with growing GDP and income per capita of Indian economy.
She is handling domestic oparations of Emcure

Satish Mehta Who is handling Overseas Business , is a qualified and experienced entrepreneur with a proven track record in the pharmaceutical industry.

(15/17)
2️⃣ Strong Brand Recognition

3️⃣ Diversified Product Portfolio

4️⃣ Expanding Global Presence through strategic acquisitions and partnerships

5️⃣ Strong R&D Capabilities

(16/17)
📌
This analysis derived from RHP & Public domain information and its only for informational purposes on Emcure , I'm not SEBI registered personnel,
Please consult with your Financial Advisor and do your due diligence before Act
Disclosure : Holding.

Thanks For Reading 🙏

(17/17)

I have 9 lots
what should i do ?
It is showing some weakness now it is below its first days low

lets see tomorrow

SL kya rhega?

Why there is too much illiquidity in Emcure ??

Not only emcure, hold tight.

​@Seth. One of my relative strongly believe it will touch 2000....

He is holding 4 bhni lot of ireda x 32/- . That makes me strongly follow him.

Today and yesterday big buyers tried to Move up above 1400⏫

But weak hands still have some quantity left and selling it

In my view , It should take 1-2 week to absorb it slowly and then it will fly subject to same stable market condition.👍
Dis : holding significant Quantity

Seems heading towards 993 ????

​@Cyberdude Yes holding it and posted notes here.
Holding for 12 months period will analyse upcoming quarterly results

Respected Sir,
I am an engineering student, I got one lot. My present income is 0, if I sell the shares should I file ITR or any tax would be there to me?
If possible guide me to resources so that I can learn all about finance!!

Thank you

​@buddhuannu You are welcome. And probably you should consider change display name to something like smartannu 😊

​@smartannu Nice to see this ID 😊👍

1408 high, thoda down karke chhote retailers ke pas se maal daba liya big retailers ne, hold karo is month me 1500 tak jarur jayega

​@NEW INVEST₹ Bhai woh aaj jaldi bazi me aaj 1400 se above aaya tab use yaad aayi ki me ghr se kuch doze lena bhul gya toh woh upis aa gya aab kal jayega upis

Expecting same. 1512 hit hi jayega.

Ab 1325 cross nahi karega na? Kitna achha stable tha, humne gaali deke iska stableness hata di.

@Dharmendra sharma should hold Bansal wire atleast 6 months doubling candidate.

Rate this photo and comment ur views and target

​@Chhote Lal @MuStrFc @diwan kapoor  and other members my amount is blocked also not submitted on exchange also mail dropped registar and sbi bank . any mebmers whom was blocked amount and not unblocked amount yet anyone knows what is processing to SEBI complaint??

I lodged complaint

Let's hope it gets tesolved. Unblocking of funds is certain but any compensation you get is to be seen. Good Luck 🤞

Wow what a confidence building chart. Just like our heartbeat...stable and in range. Products can be trusted😁👍

Emcure to 1360/1361

​@GrayIsTheNewBlack But now it is showing some strength. Touched 1372 and presently at 1365 😊